Hypothyroidism

Hypothyroidism is an endocrine disorder in which insufficient thyroid hormone production or stimulation results in inadequate thyroid hormone action in the body. These hormones help regulate metabolism, heat production, and the functioning of many organs, and are essential for normal growth and brain development. Most cases originate in the thyroid gland itself; less commonly, impaired signaling from the pituitary gland or hypothalamus causes central hypothyroidism. The condition differs from hyperthyroidism, in which thyroid hormone production is excessive. (thyroid.org)

Causes include autoimmune thyroid disease, iodine deficiency, thyroid surgery or radiation treatment, certain medications, and congenital abnormalities. Symptoms often develop gradually and can include fatigue, cold intolerance, constipation, dry skin, and weight gain, but symptoms alone cannot establish the diagnosis. Blood measurements of thyroid-stimulating hormone and free thyroxine distinguish major biochemical forms. Treatment generally uses levothyroxine to replace deficient hormone, with laboratory monitoring to assess replacement. (niddk.nih.gov)

Hypothyroidism has particular significance during pregnancy and early childhood because thyroid hormone availability affects fetal and infant development. Its clinical spectrum extends from subclinical biochemical abnormalities to rare, life-threatening decompensation known as myxedema coma. Understanding the disorder therefore involves its physiology, causes, population distribution, diagnostic methods, treatment, and age-specific consequences, as well as the history of thyroid hormone replacement and screening. (thyroid.org)

Thyroid hormone physiology and deficiency

The thyroid gland is organized into follicles: spherical structures lined by a single layer of epithelial cells and containing a central reservoir of colloid. The cells face blood capillaries on their outer surface and colloid on their inner surface, allowing coordinated uptake, synthesis, storage, and secretion. Colloid consists principally of thyroglobulin, a large protein that provides the framework for producing thyroid hormones. Follicular cells take up iodide from the circulation through the sodium–iodide symporter and transport it toward the follicular lumen. At the cell–colloid boundary, the enzyme thyroid peroxidase uses hydrogen peroxide to catalyze the incorporation of iodine into tyrosine residues within thyroglobulin. Coupling two diiodinated residues produces thyroxine (T4), whereas coupling a monoiodinated and a diiodinated residue produces triiodothyronine (T3). The names reflect their four and three iodine atoms, respectively. (ncbi.nlm.nih.gov)

The hormones remain attached to thyroglobulin during storage in the follicular lumen. For secretion, follicular cells internalize hormone-bearing thyroglobulin and digest it in lysosomes, releasing T4 and T3 into the bloodstream; iodine from uncoupled iodinated residues is recycled within the gland. T4 is the predominant secreted hormone. In blood, most thyroid hormone is bound to carrier proteins, especially thyroxine-binding globulin, transthyretin, and albumin. Only a small fraction circulates unbound: approximately 0.03% of total T4 is free T4. Protein binding provides a circulating reservoir, while the free fraction is available for uptake into tissues. (ncbi.nlm.nih.gov)

Production is regulated by the hypothalamic–pituitary–thyroid axis. The hypothalamus releases thyrotropin-releasing hormone (TRH), which stimulates thyrotroph cells in the anterior pituitary to synthesize and secrete thyroid-stimulating hormone (TSH). TSH binds receptors on thyroid follicular cells, stimulating iodide uptake, hormone synthesis and release, and maintenance of glandular tissue. Circulating thyroid hormones exert negative feedback on the hypothalamus and pituitary, reducing TRH and TSH production when hormone availability rises. Local conversion of T4 to T3 within these regulatory tissues contributes to that feedback signal. When the thyroid itself cannot produce sufficient hormone, declining feedback ordinarily increases TSH secretion; failure of hypothalamic or pituitary signaling can instead leave the gland inadequately stimulated. (ncbi.nlm.nih.gov)

T4 functions largely as a precursor for the more biologically active T3. Approximately 80% of circulating T3 is generated outside the thyroid through removal of an iodine atom from T4. Type 1 and type 2 deiodinases catalyze this activation, whereas type 3 deiodinase inactivates thyroid hormones, converting T4 to reverse T3 and T3 to diiodothyronine. Tissue-specific transport and deiodinase activity allow organs to regulate intracellular hormone availability rather than relying solely on circulating concentrations. T3 binds nuclear thyroid hormone receptors, which regulate gene expression involved in energy use, cellular differentiation, and organ function. (thyroid.org)

Thyroid hormone supports resting energy expenditure and heat production by regulating processes including mitochondrial energy metabolism and the maintenance of cellular ion gradients. It also supports adaptive thermogenesis, particularly through interaction with sympathetic signaling in brown adipose tissue. Deficiency therefore lowers metabolic activity and heat production, contributing to cold intolerance, while reduced hormone action can slow intestinal motility and impair cardiac, muscular, and cognitive function. During development, thyroid hormone is essential for normal brain maturation and physical growth. These effects reflect altered tissue signaling, not simply a shortage of dietary energy: changes in hormone availability modify the cellular programs governing metabolism, thermoregulation, and development. (pmc.ncbi.nlm.nih.gov)

Clinical and biochemical classification

Primary hypothyroidism results from failure of the thyroid gland itself to produce sufficient thyroid hormone. The pituitary ordinarily responds to declining hormone availability by increasing thyroid-stimulating hormone (TSH), so an elevated TSH is characteristic of primary disease. Secondary hypothyroidism originates in the pituitary, whereas tertiary hypothyroidism originates in the hypothalamus, which normally supplies thyrotropin-releasing hormone to stimulate pituitary TSH secretion. Secondary and tertiary disease are grouped as central hypothyroidism because both impair stimulation of the thyroid rather than primarily damaging the gland. These anatomical categories identify the level of dysfunction, not its clinical severity. (thyroid.org)

Within primary disease, overt hypothyroidism is defined biochemically by TSH above the applicable reference interval together with free thyroxine (free T4, or FT4) below its reference interval. Subclinical hypothyroidism denotes elevated TSH with FT4 still within the reference interval. Free T4 is the circulating fraction not bound to transport proteins; total T4 includes both bound and unbound hormone and can change when binding-protein concentrations change. The overt–subclinical distinction therefore depends on paired measurements, not on TSH alone or the presence of symptoms. “Subclinical” does not simply mean that no symptoms exist, and a normal triiodothyronine (T3) concentration does not exclude overt disease: T3 can remain normal despite elevated TSH and low FT4. (thyroid.org)

Central disease requires a different interpretation. Low FT4 accompanied by low or normal TSH is abnormal because TSH has failed to rise appropriately in response to hormone deficiency. Occasionally, TSH is mildly elevated but remains inadequate for the degree of FT4 reduction; consequently, central disease cannot always be distinguished from primary disease by whether TSH exceeds the laboratory upper limit. The 2018 European Thyroid Association guidelines specify confirmation of low FT4 with inappropriately low or normal TSH on two separate determinations, after excluding conditions that can mimic this pattern. The usual definition of subclinical primary hypothyroidism should not be transferred directly to hypothalamic–pituitary disease. (pmc.ncbi.nlm.nih.gov)

Congenital and acquired describe timing rather than anatomical origin. Congenital hypothyroidism is present at birth; examples include an absent, underdeveloped, or ectopically located thyroid and defects in hormone synthesis. Congenital central forms also occur. Acquired disease develops after birth, including during childhood or adulthood, and may follow autoimmune disease, thyroid surgery, or damage to hypothalamic–pituitary structures. Congenital does not necessarily mean inherited: most thyroid developmental abnormalities are sporadic, whereas some hormone-synthesis defects are inherited. Newborns may have few obvious symptoms despite biochemical deficiency, so clinical appearance does not determine this classification. (thyroid.org)

Permanent and transient describe duration. Absence of the thyroid represents permanent loss of hormone-producing capacity, whereas maternal thyroid-blocking antibodies can cause neonatal deficiency lasting weeks to months. Acquired deficiency after thyroiditis may resolve, although some cases become permanent. Thus, neither congenital onset nor an overt biochemical pattern establishes lifelong persistence. Likewise, biochemical severity and symptom severity are not interchangeable: subclinical disease commonly causes few or no symptoms, while fatigue, cold intolerance, and constipation are nonspecific and may arise from other conditions. Laboratory categories describe hormone status; they do not provide a direct scale of symptom burden. (thyroid.org)

Epidemiology and susceptibility

In the United States, Joseph G. Hollowell and colleagues’ analysis of the 1988–1994 National Health and Nutrition Examination Survey (NHANES III), published in 2002, measured thyroid function in 17,353 participants aged 12 years or older. The estimated prevalence of biochemical hypothyroidism was 4.6%: 0.3% overt disease and 4.3% subclinical disease. The study defined overt hypothyroidism as thyroid-stimulating hormone (TSH) above 4.5 mIU/L together with total thyroxine (T4) below 57.9 nmol/L; subclinical disease had TSH above that threshold without low total T4. These were survey-specific biochemical definitions, using total rather than free T4, and the overall sample included people reporting thyroid disease or taking thyroid medication. The frequently quoted estimate of approximately five affected people per 100 Americans aged 12 or older therefore includes subclinical disease, rather than describing overt hormone deficiency alone. (pubmed.ncbi.nlm.nih.gov)

The subsequent NHANES 1999–2002 analysis reported a combined overt and mild hypothyroidism prevalence of 3.7% among people aged 12 years or older, comprising 0.3% overt and 3.4% mild disease. Its laboratory classification likewise used elevated TSH, with total T4 distinguishing overt from mild disease. Estimates that combine these categories are not interchangeable with estimates restricted to overt disease, previously diagnosed cases, or populations excluding thyroid medication users. Both surveys measured thyroid status at a particular examination; their percentages describe prevalence, not the annual incidence of newly developing disease. (pubmed.ncbi.nlm.nih.gov)

Women and older adults have higher occurrence, although the magnitude depends on the population and biochemical definition. In NHANES 1999–2002, combined overt and mild disease affected 4.2% of females and 3.1% of males. Prevalence increased from 2.4% at ages 12–49 to 5.5% at ages 50–79 and 12.1% at age 80 or older. Subclinical or mild disease accounted for most cases in each age group. NHANES III also found that thyroid autoantibodies were more frequent in women and increased with age, providing an epidemiological connection between these demographic patterns and thyroid autoimmunity. (journals.sagepub.com)

Susceptibility is also associated with a family history of thyroid disease and with previous thyroid abnormalities, including goiter or hyperthyroidism. A history of thyroid surgery, radioactive iodine treatment, or irradiation involving the thyroid or neck identifies additional susceptible groups. These histories differ in significance: family history indicates familial susceptibility, whereas treatment-related loss or injury of thyroid tissue can directly reduce hormone-producing capacity. The mechanisms of these acquired causes are distinct from the demographic associations observed in population surveys. (niddk.nih.gov)

Type 1 diabetes, other autoimmune disorders, and Down syndrome are associated with increased susceptibility. Recognized autoimmune associations include celiac disease, Sjögren syndrome, pernicious anemia, rheumatoid arthritis, and lupus. The 2015 US Preventive Services Task Force statement specifically lists type 1 diabetes and Down syndrome among risk factors for elevated TSH. These are associations rather than deterministic relationships: membership in a susceptible group does not establish thyroid hormone deficiency, and an elevated TSH can represent subclinical rather than overt disease. (niddk.nih.gov)

Autoimmune thyroid destruction

Hashimoto thyroiditis, also called chronic lymphocytic thyroiditis, is an autoimmune disease and the most common cause of hypothyroidism in the United States. The immune system targets thyroid tissue: lymphocytes accumulate within the gland, thyroid-directed antibodies develop, and sustained inflammation damages hormone-producing cells. Loss of functioning tissue reduces the gland’s capacity to produce thyroxine (T4) and triiodothyronine (T3). This process often develops slowly over years, so autoimmune thyroid disease may precede measurable hormone deficiency or recognizable symptoms. Hashimoto thyroiditis therefore identifies an underlying disease process, not necessarily a state of hypothyroidism at the time it is identified. (niddk.nih.gov)

Cellular and antibody-mediated immune responses both contribute to injury; destruction is not simply the consequence of a positive antibody test. Research has linked thyroid-directed immune activity to cytokines produced by T lymphocytes, which can contribute to thyroid-cell damage and death. In a 2005 study, George Karanikas and colleagues found that higher thyroid peroxidase antibody titres correlated with increased frequencies of T cells producing particular inflammatory cytokines. The result associated antibody concentrations with cellular immune activity, rather than establishing antibodies as the sole mechanism of destruction. As damage accumulates, the remaining tissue may no longer sustain adequate hormone production. (onlinelibrary.wiley.com)

The principal circulating autoantibodies measured are antibodies against thyroid peroxidase, designated TPOAb or anti-TPO, and against thyroglobulin, designated TgAb or anti-Tg. Thyroid peroxidase is an enzyme involved in iodinating thyroglobulin during hormone synthesis; thyroglobulin is the thyroid protein on which hormone precursors are assembled. These antibodies serve as markers of thyroid autoimmunity. Their presence in a person with biochemical hypothyroidism supports an autoimmune cause, but their presence alone does not demonstrate hormone deficiency. For example, an antibody-positive person may have both thyroid-stimulating hormone (TSH) and free T4 within their reference intervals. Conversely, some people with suspected Hashimoto thyroiditis lack detectable circulating antithyroid antibodies. Actual thyroid function is assessed using TSH and free T4, not antibody titre; serial antibody measurements do not reliably establish progression to deficiency or response to replacement. (pubmed.ncbi.nlm.nih.gov)

Autoimmune thyroiditis can have goitrous or atrophic presentations. In the goitrous form, inflammation accompanies enlargement of the gland, sometimes producing neck fullness, pressure, or difficulty swallowing; the enlargement is usually painless. In the atrophic presentation, the gland is small rather than enlarged. A previously enlarged thyroid may shrink after years or decades of damage, so disappearance of a goitre does not necessarily indicate recovery of function. Preserved thyroid function can progress to elevated TSH with normal free T4 and subsequently to overt deficiency, but this sequence is not inevitable in every antibody-positive individual. Established hypothyroidism from Hashimoto thyroiditis is usually persistent. (niddk.nih.gov)

A distinct autoimmune mechanism is inhibition of TSH action by receptor-blocking antibodies, which can impair secretion without requiring complete destruction of the gland. In a 1992 study, Nobuyuki Takasu and colleagues detected thyrotropin-blocking antibodies in 9% of 172 hypothyroid patients with goitrous autoimmune thyroiditis and 25% of 64 with atrophic autoimmune thyroiditis. Among 21 antibody-positive patients followed longitudinally, the blocking antibodies disappeared in 15; six of those remained euthyroid after supervised withdrawal of replacement therapy. This selected cohort demonstrated that autoimmune inhibition can sometimes be reversible, while not establishing a general recovery rate for Hashimoto thyroiditis. (pubmed.ncbi.nlm.nih.gov)

Nonautoimmune causes of acquired primary disease

Iodine deficiency limits the substrate required to synthesize thyroxine (T4) and triiodothyronine (T3). Compensatory elevation of thyroid-stimulating hormone (TSH) increases iodine trapping and stimulates thyroid enlargement, producing a goiter; these adaptations can preserve hormone output in milder deficiency, whereas sufficiently severe deficiency causes hypothyroidism. Iodine excess acts differently: a large iodide load temporarily inhibits iodine organification—the incorporation of iodine into hormone precursors—and hormone synthesis through the Wolff–Chaikoff effect. Normal adaptation involves reducing iodide transport into thyroid cells, allowing synthesis to resume. Failure to escape this inhibition can produce persistent deficiency, particularly in a previously damaged gland. Relevant exposures include iodine-rich seaweed or supplements, iodinated contrast agents, and iodine-containing medicines. Excess iodine can therefore suppress production rather than simply supply additional raw material. (ncbi.nlm.nih.gov)

Removal or destruction of functioning thyroid tissue reduces the gland’s capacity to produce hormones. Total thyroidectomy eliminates endogenous thyroid production, whereas partial removal may leave sufficient tissue to maintain normal function; the outcome depends on the quantity and functional reserve of the remaining gland. Radioactive iodine used for hyperthyroidism or thyroid cancer is concentrated by thyroid cells and destroys functioning tissue, potentially producing permanent hypothyroidism. External-beam radiation therapy involving the thyroid, such as treatment for head-and-neck cancers or lymphoma, can also damage the gland. Unlike complete surgical removal, radiation-related failure may develop gradually, with hormone deficiency becoming apparent months or years after exposure. (thyroid.org)

Medication-induced disease includes direct inhibition of hormone production or release. Lithium, used in mood disorders, inhibits thyroid hormone release and can cause compensatory TSH elevation, goiter, and hypothyroidism. Experimental studies demonstrate inhibition both of cyclic-AMP generation and of subsequent steps in TSH-stimulated hormone release. Amiodarone, an antiarrhythmic drug containing approximately 37% iodine by weight, delivers a substantial iodine load that can sustain inhibition of thyroid hormone synthesis. It also inhibits conversion of T4 to T3, so reduced T3 during treatment does not by itself establish gland failure. The 2018 European Thyroid Association guideline distinguishes these expected biochemical effects from amiodarone-induced hypothyroidism; the latter can occur in an apparently normal gland as well as one with underlying thyroid disease. (thyroid.org)

Drugs that modify the immune system provide an important overlap between medication-related and autoimmune causes. Interferon alfa and interleukin-2 can trigger thyroid dysfunction. Immune checkpoint inhibitors, including pembrolizumab and nivolumab, may provoke inflammatory thyroid injury by altering immune regulation. The resulting destructive thyroiditis can initially release stored hormone and subsequently leave insufficient functioning tissue, producing hypothyroidism. These are acquired treatment-associated causes, but their mechanisms are not necessarily nonautoimmune: an external drug exposure can initiate immune-mediated gland damage. (thyroid.org)

Destructive thyroiditis differs from sustained inhibition of synthesis because damaged follicles first leak preformed hormone into the circulation. A thyrotoxic phase may therefore precede hypothyroidism, although not every patient experiences both phases. Once stored hormone is depleted, output remains low until follicular function recovers; extensive damage instead leaves permanent deficiency. Painful subacute thyroiditis illustrates this usually reversible course: the American Thyroid Association describes restoration of normal function within approximately 12–18 months in most patients, with about 5% developing permanent hypothyroidism. Painless and postpartum thyroiditis can follow a similar sequence, although their autoimmune and pregnancy-related features belong to their respective etiological contexts. A hypothyroid phase after destructive inflammation therefore does not, by itself, demonstrate irreversible gland failure. (thyroid.org)

Central hypothyroidism

Central hypothyroidism results from inadequate stimulation of the thyroid by the pituitary gland or hypothalamus, rather than destruction of thyroid tissue. Acquired causes include pituitary adenomas and craniopharyngiomas, damage following surgery or cranial irradiation, head trauma, and vascular injury such as pituitary apoplexy. Lesions may impair TSH-producing cells, interrupt hypothalamic signaling through the pituitary stalk, or reduce the biological activity of secreted TSH. Congenital causes include pituitary developmental abnormalities and defects in genes governing hormone production or pituitary differentiation, such as TSHB, TRHR, POU1F1, and PROP1. These defects can produce isolated TSH deficiency or combined pituitary hormone deficiencies. (endo-ern.eu)

A specific inherited example was established in 2012 by Yu Sun, Beata Bak, Nadia Schoenmakers, and colleagues. Their study identified eight distinct mutations and two deletions in IGSF1 among males from 11 unrelated families with central hypothyroidism, testicular enlargement, and variably low prolactin concentrations. The disease-associated variants impaired expression or cell-surface trafficking of the IGSF1 membrane protein. Experiments in deficient mice also found reduced pituitary TRH-receptor expression, supporting impaired hypothalamic–pituitary signaling as a mechanism. The disorder illustrates that a congenital central defect need not involve a visible mass or generalized pituitary failure. (pmc.ncbi.nlm.nih.gov)

The characteristic biochemical finding is free thyroxine (free T4) below the laboratory reference interval with an inappropriately low, normal, or mildly elevated TSH. A normal TSH is inappropriate because reduced thyroid hormone would ordinarily provoke a substantial compensatory increase. In some hypothalamic disorders, circulating TSH remains detectable by immunoassay but has reduced biological activity, explaining occasional mild elevations despite deficient thyroid stimulation. Consequently, testing strategies that measure free T4 only when TSH is abnormal can miss central disease. The 2018 European Thyroid Association guideline calls for confirmation on two separate determinations after excluding mimics, including severe nonthyroidal illness, medication effects, and assay interference. (pmc.ncbi.nlm.nih.gov)

Evaluation extends beyond the thyroid axis because central hypothyroidism may accompany hypopituitarism. Assessment can include prolactin, gonadotropins and sex hormones, and investigation of growth-hormone deficiency; the tests depend on the clinical presentation. Pituitary magnetic resonance imaging delineates structural lesions and their relationship to surrounding tissues. When a mass abuts the optic nerves or chiasm, formal visual-field testing assesses associated compression. Imaging identifies an anatomical cause, whereas hormone measurements establish which endocrine functions are impaired; neither substitutes for the other. (endocrine.org)

Adrenal function is particularly important because ACTH deficiency can coexist with central thyroid deficiency. The Endocrine Society’s 2016 guideline specifies serum cortisol measured at 8–9 a.m. as the initial assessment, with corticotropin stimulation testing when the result is indeterminate. Thyroid hormone replacement increases cortisol clearance and can precipitate adrenal crisis in an individual with unrecognized cortisol deficiency. Accordingly, published guidelines place assessment of adrenal reserve before thyroid replacement and specify glucocorticoid coverage when concomitant adrenal insufficiency has not been excluded. (endocrine.org)

Symptoms and physical signs

Fatigue, reduced stamina, sleepiness, and cold intolerance are common manifestations of thyroid hormone deficiency. Reduced metabolic activity and heat production can make an affected person feel cold in an environment that others find comfortable. Symptoms usually accumulate over months or years, although their onset can be faster. Their intensity does not reliably measure biochemical severity: some people with markedly abnormal thyroid tests report few symptoms, whereas mild or subclinical disease may produce no recognizable complaints. These manifestations are nonspecific, and their presence alone does not establish the diagnosis. (thyroid.org)

Gastrointestinal slowing commonly presents as new or worsening constipation. Weight gain may occur despite reduced appetite, but it is generally modest rather than an explanation for substantial obesity. The American Thyroid Association’s 2019 patient booklet describes a gain of approximately 5–20 pounds (2–9 kg); this is a descriptive range, not a diagnostic threshold. Weight change can include retained fluid as well as changes in body composition, so an increase on the scale is not equivalent to an increase in adipose tissue. Dry, itchy skin, reduced sweating, and hair that becomes coarse, brittle, or thin are additional manifestations. Hair loss varies considerably between individuals. (thyroid.org)

Cognitive and emotional complaints include forgetfulness, slower thinking, difficulty concentrating, and depressed mood. These may resemble depression or other conditions without identifying a thyroid cause. Neuromuscular manifestations include muscle weakness, aching, stiffness, and cramps; tingling in the hands or feet and carpal tunnel symptoms can also occur. Menstrual changes may include heavier or more frequent bleeding and increased cramping. None of these symptoms is specific to hypothyroidism, and affected individuals need not experience the entire pattern. (thyroid.org)

Physical examination may reveal a slow resting pulse, cool or coarse skin, and delayed relaxation of deep-tendon reflexes. The reflex abnormality is particularly apparent after eliciting the Achilles tendon reflex: the calf contracts but returns to its resting state unusually slowly. It therefore concerns the relaxation phase, rather than simply an absent or weak reflex. Thyroid hormone deficiency reduces skeletal-muscle calcium-pump activity, impairing calcium reuptake into the sarcoplasmic reticulum and slowing relaxation. A 1958 report by Sheldon S. Waldstein and colleagues described this phenomenon in the biceps and Achilles reflexes and discussed earlier recordings in which relaxation was prolonged beyond the normal range in 77% of patients with myxedema; that historical figure is not a sensitivity estimate for all contemporary presentations of hypothyroidism. (endotext.org)

Hoarseness and a puffy appearance, especially around the eyes, may accompany more established disease. Myxedema denotes the characteristic mucinous, nonpitting tissue swelling associated with substantial thyroid hormone deficiency. Hyaluronic acid and other glycosaminoglycans accumulate in the interstitial tissues and bind water, producing swelling that does not leave the persistent indentation typical of pitting edema. This tissue change is distinct from ordinary fat-related weight gain, even though both can increase body weight or apparent bulk. Myxedematous swelling is not synonymous with myxedema coma, the separate syndrome of severe physiological decompensation. (thyroid.org)

Systemic complications

Overt thyroid hormone deficiency commonly raises total and low-density lipoprotein (LDL) cholesterol. Reduced hepatic LDL-receptor expression slows removal of LDL from the circulation; diminished activity of lipid-processing enzymes can also impair clearance of triglyceride-rich lipoproteins. Triglyceride concentrations may therefore rise, although this change is less consistent than the increase in LDL cholesterol. These metabolic effects are generally more pronounced in overt than in subclinical disease. Independently of lipid changes, hypothyroidism reduces myocardial contractility and cardiac output while increasing systemic vascular resistance. The resulting cardiovascular pattern can include a slow heart rate, impaired ventricular relaxation, reduced exercise tolerance, and predominantly diastolic hypertension. (academic.oup.com)

These physiological abnormalities must be distinguished from estimates of future coronary artery disease. In a 2010 individual-participant analysis led by Nicolas Rodondi, 11 prospective cohorts contributed 55,287 adults. Subclinical hypothyroidism was defined by thyroid-stimulating hormone (TSH) concentrations of 4.5–19.9 mIU/L with normal thyroxine concentrations. Compared with euthyroid participants, the age- and sex-adjusted hazard ratio for coronary events was 1.00 (95% confidence interval, 0.86–1.18) at TSH 4.5–6.9 mIU/L, but 1.89 (1.28–2.80) at TSH 10–19.9 mIU/L. Overall mortality was not increased. These observational associations do not establish causation or demonstrate that correcting a mild biochemical abnormality prevents coronary events. (pubmed.ncbi.nlm.nih.gov)

Substantial, prolonged deficiency can produce pericardial effusion, the accumulation of fluid around the heart. Increased permeability of epicardial vessels and reduced lymphatic drainage allow albumin-rich fluid to collect in the pericardial space. Accumulation is usually slow, so even a large effusion may cause few symptoms; cardiac tamponade, in which fluid pressure compromises cardiac filling, is uncommon. Respiratory impairment can arise from both respiratory-muscle weakness and diminished ventilatory responses to carbon dioxide or low oxygen. In a 1988 study by Paul Ladenson and colleagues involving 38 hypothyroid patients, responses to carbon dioxide were blunted in 10 of 29 tested participants, and responses to hypoxia were abnormal in eight of 30. These selected clinical observations describe possible mechanisms of hypoventilation, not its prevalence in all people with hypothyroidism. (pubmed.ncbi.nlm.nih.gov)

Severe deficiency can impair renal water excretion and contribute to dilutional hyponatremia. Reduced cardiac output and renal blood flow can lower glomerular filtration, while altered vasopressin regulation and renal water handling may further restrict free-water clearance. Clinically important sodium reduction is principally associated with severe decompensated disease rather than uncomplicated mild hypothyroidism; concurrent illness, medications, or adrenal insufficiency may contribute. A low sodium concentration therefore cannot automatically be attributed to thyroid hormone deficiency. (pmc.ncbi.nlm.nih.gov)

Neuromuscular complications extend beyond nonspecific cramps and tiredness to clinically demonstrable myopathy, peripheral nerve dysfunction, and nerve entrapment such as carpal tunnel syndrome. In a prospective clinical and electrodiagnostic study published in 2000, 38% of the hypothyroid patients had objective muscle weakness, 42% had signs of sensorimotor axonal neuropathy, and 29% had carpal tunnel syndrome. Serum creatine kinase did not correlate with the degree of weakness. These figures describe a clinical cohort, rather than population-wide complication rates. (pubmed.ncbi.nlm.nih.gov)

Reproductive effects include impaired ovulation, heavy menstrual bleeding, infrequent periods, and reduced fertility, but normal menstruation remains common. Altered gonadotropin signaling can disrupt the ovulatory surge; anovulation and changes in hemostasis can contribute to excessive bleeding. In a 1999 study by Gerasimos Krassas and colleagues, menstrual irregularities occurred in 23.4% of 171 premenopausal hypothyroid patients, compared with 8.4% of 214 controls; infrequent menstruation and heavy bleeding were the principal abnormalities. The patient group included subclinical, mild, and severe disease, so this estimate does not apply exclusively to overt hypothyroidism. (ncbi.nlm.nih.gov)

Diagnostic evaluation and test interpretation

Serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) provide complementary information: TSH reflects the pituitary response to thyroid hormone availability, whereas FT4 measures circulating thyroxine not bound to transport proteins. In adults without suspected pituitary disease, NICE recommends initial TSH measurement, followed by FT4 testing in the same sample when TSH exceeds the reference interval. Elevated TSH with low FT4 supports overt primary deficiency; elevated TSH with normal FT4 identifies a subclinical biochemical pattern. When pituitary disease is suspected, both tests are measured initially because a normal TSH does not exclude central deficiency. These patterns establish functional status rather than the underlying cause. (nice.org.uk)

Results require the reporting laboratory’s reference intervals rather than a universal cutoff. The American Thyroid Association describes approximately 0.4–4.0 mIU/L as a commonly used adult TSH interval, while noting variation between laboratories and populations. Age and pregnancy also affect interpretation. FT4 is generally more informative than total T4 when hormone-binding protein concentrations change, because total T4 includes both bound and unbound hormone. Routine triiodothyronine (T3) measurement adds little to the diagnosis of deficiency: T3 may remain normal despite elevated TSH and substantially reduced FT4. Conversely, low T3 can occur during systemic illness without primary thyroid failure. Thus, neither normal nor low T3 alone establishes thyroid status. (thyroid.org)

Testing for thyroid peroxidase antibodies, and sometimes thyroglobulin antibodies, addresses etiology. These autoantibodies support thyroid autoimmunity, but their presence does not itself demonstrate inadequate hormone production; TSH and FT4 remain the functional measurements. NICE recommends considering thyroid peroxidase antibody measurement in adults with elevated TSH and does not recommend routinely repeating it. Structural assessment answers a different question: ultrasonography can demonstrate enlargement, nodules, or altered gland appearance, but these findings do not establish hormone deficiency. An underactive gland may appear normal, enlarged, or small, and an abnormal-looking gland may retain normal function. (nice.org.uk)

Acute systemic illness can alter thyroid hormone metabolism and hypothalamic–pituitary signaling, producing low T3, variable FT4, and low or normal TSH; TSH may transiently rise during recovery. This nonthyroidal illness pattern can resemble thyroid disease without representing persistent gland failure. NICE therefore discourages testing during acute illness unless thyroid dysfunction is suspected as its cause. Medication history also matters: dopamine and glucocorticoids can suppress TSH secretion, making an isolated TSH result misleading. Interpretation consequently incorporates illness severity, recovery phase, and drug exposure rather than treating every out-of-range result as a new endocrine diagnosis. (nice.org.uk)

Analytical interference is particularly relevant when laboratory findings conflict with the clinical picture. High-dose biotin, including supplements marketed for hair and nails, can interfere with assays that use biotin-dependent detection systems. A common misleading pattern is falsely low TSH with falsely high T4 or T3, mimicking hyperthyroidism or concealing deficiency; susceptibility varies by assay. NICE added an explicit recommendation to ask about biotin intake in 2023. The distinction is between altered hormone concentrations in the patient and distortion of the laboratory measurement itself. (thyroid.org)

A single mildly elevated TSH does not necessarily establish persistent disease. The USPSTF’s 2015 statement describes repeat testing over three to six months to confirm abnormalities in nonpregnant, asymptomatic adults, particularly when results are only modestly outside the reference interval. This confirmation approach differs from evaluation of marked biochemical deficiency or significant clinical illness. Nonspecific symptoms also require a broader differential diagnosis: fatigue, cognitive complaints, and weight change may accompany anemia, iron deficiency, depression, inadequate sleep, or menopause. These conditions can coexist with thyroid disease, so their presence neither confirms nor excludes hormone deficiency. (uspreventiveservicestaskforce.org)

Subclinical hypothyroidism and natural history

Subclinical hypothyroidism—elevated thyroid-stimulating hormone (TSH) with free thyroxine (free T4) within the reference interval—is not necessarily an irreversible stage preceding overt disease. Longitudinal studies identify three principal outcomes: persistent biochemical abnormality, spontaneous normalization, and progression to overt hypothyroidism, in which free T4 falls below its reference interval. Repeat measurements distinguish sustained dysfunction from a temporary TSH elevation; the 2013 European Thyroid Association (ETA) guideline specifies reassessment after approximately two to three months. Recovery from nonthyroidal illness and transient thyroiditis can produce elevations that subsequently resolve. (pmc.ncbi.nlm.nih.gov)

The 2015 US Preventive Services Task Force statement summarized a prospective study of 107 adults aged at least 55 years whose TSH exceeded 5 mIU/L on two measurements before enrollment. Without intervention, 40 participants, or 37%, returned to normal thyroid function during a mean follow-up of 32 months. Persistence was nevertheless common in a larger population-based investigation: Lily Somwaru and colleagues’ 2012 Cardiovascular Health Study analysis identified 459 untreated participants with subclinical hypothyroidism among 3,996 US adults aged at least 65 years. Approximately 56% had subclinical hypothyroidism at each of the two- and four-year assessments. These observations show why a single abnormal result does not establish permanent thyroid failure. (uspreventiveservicestaskforce.org)

Initial TSH concentration strongly predicted the subsequent course in the Cardiovascular Health Study. At two years, normalization occurred in 46% of participants with baseline TSH of 4.5–6.9 mIU/L, compared with 10% at 7.0–9.9 mIU/L and 7% at 10 mIU/L or higher. Normalization also occurred more frequently in those without thyroid peroxidase autoantibodies than in antibody-positive participants: 48% versus 15%. TSH of at least 10 mIU/L independently predicted progression to overt disease. Antibody positivity identifies thyroid autoimmunity, but neither positivity nor a higher TSH makes progression inevitable; these figures describe an older cohort rather than universal probabilities. (pubmed.ncbi.nlm.nih.gov)

Underlying thyroid damage also influences assessment of persistence. NICE guideline NG145, published in 2019, identifies previous thyroid surgery, radioactive iodine treatment, and raised thyroid autoantibodies as evidence relevant to treatment decisions. It suggests measuring thyroid peroxidase antibodies in adults with elevated TSH, without repeating antibody measurements routinely. For untreated adults, its monitoring framework distinguishes those with evidence of underlying disease—annual TSH and free T4 measurements—from those without such features, for whom measurements every two to three years are considered. This separates etiological risk assessment from serial measurement of thyroid function itself. (nice.org.uk)

Published guidelines give persistent TSH elevations around 10 mIU/L greater weight than milder abnormalities. NICE recommends considering levothyroxine in adults with TSH of at least 10 mIU/L on two occasions three months apart. Below that threshold, it limits consideration of a six-month therapeutic trial to symptomatic adults under 65 with similarly confirmed elevation. The 2013 ETA adult guideline recommends replacement for people younger than approximately 65–70 years with TSH above 10 mIU/L, even without symptoms, while generally favoring observation in those over 80–85 with TSH no higher than 10 mIU/L. The ETA document explicitly excludes childhood and pregnancy, which require separate criteria. (nice.org.uk)

Evidence that biochemical correction improves symptoms is more limited than evidence describing natural history. In the 2017 TRUST randomized controlled trial, David Stott and colleagues studied 737 adults aged at least 65 years with persistent subclinical hypothyroidism. Levothyroxine lowered TSH but did not improve hypothyroid-symptom or tiredness scores relative to placebo at one year; mean baseline TSH was 6.40 mIU/L. Thus, its findings chiefly inform older adults with mild elevations and do not directly establish treatment effects in younger symptomatic populations or predominantly higher-TSH populations. NICE separately identifies treatment of symptomatic adults under 65 as a research question. (nejm.org)

Congenital hypothyroidism and childhood disease

Congenital thyroid hormone deficiency can result from thyroid dysgenesis: an absent gland, an underdeveloped gland, or thyroid tissue in an abnormal location. These developmental abnormalities are usually sporadic. In thyroid dyshormonogenesis, the gland is present but cannot synthesize sufficient hormone; inherited forms may follow autosomal recessive inheritance, with a 25% recurrence probability in each pregnancy when both parents carry the same causal defect. Transient neonatal deficiency can arise when maternal blocking autoantibodies cross the placenta and inhibit thyroid stimulation, or when maternal antithyroid medication suppresses fetal hormone production. Excessive maternal iodine intake can also impair neonatal thyroid function. These temporary causes differ from permanent loss or maldevelopment of thyroid tissue. (thyroid.org)

Most affected newborns initially have no obvious symptoms, making clinical examination alone inadequate for detection. Maternal thyroxine transferred across the placenta provides some protection before birth, but does not necessarily prevent consequences of severe fetal deficiency. When symptoms emerge, they may include prolonged jaundice, feeding difficulty, poor muscle tone, a large tongue, a hoarse cry, and constipation. Newborn screening commonly uses heel-prick blood collected on filter paper at approximately 1–2 days of age. Depending on the program, the laboratory measures thyroid-stimulating hormone (TSH), thyroxine (T4), or both. An abnormal result requires confirmatory serum TSH and free T4 testing rather than reliance on another screening blood spot alone. (thyroid.org)

Screening strategy affects which disorders are detected. TSH-based screening is sensitive for primary thyroid failure, but can miss central deficiency, in which TSH is not appropriately elevated; adding T4 measurement improves detection of central disease. Premature, low-birthweight, and sick newborns may also have false-negative initial results. The 2020–2021 European consensus therefore describes repeat sampling at approximately 10–14 days for these groups. Confirmatory results are interpreted using age-specific reference intervals. Ultrasonography or radionuclide imaging can clarify whether thyroid tissue is absent, ectopic, or normally located, but etiological imaging should not delay replacement. (pmc.ncbi.nlm.nih.gov)

Thyroid hormone is particularly important for brain development before birth and during the first two to three years. Early levothyroxine replacement generally permits normal growth and development; prolonged untreated deficiency can cause irreversible neurodevelopmental impairment. The 2020–2021 consensus specifies initiation as soon as possible, ordinarily no later than two weeks after birth, with initial biochemical follow-up after one to two weeks. Severe congenital disease can nevertheless leave subtle cognitive or motor deficits despite early treatment. Where permanence remains uncertain, supervised reassessment at age two to three years can distinguish continuing deficiency from transient disease. (thyroid.org)

Acquired childhood disease most often results from Hashimoto thyroiditis, an autoimmune disease that progressively damages thyroid tissue. Slowing linear growth is an important early manifestation; adolescents may have delayed puberty, and an enlarged thyroid may be apparent. Fatigue, cold intolerance, and constipation are less specific. Evaluation combines TSH and free T4, while thyroid autoantibodies help establish autoimmune etiology without themselves proving hormone deficiency. Pediatric monitoring also follows height gain and pubertal progression. The American Thyroid Association describes laboratory reassessment 4–8 weeks after starting levothyroxine or changing its dose, and approximately every 3–12 months in older children until growth and puberty are complete. Replacement requirements can change with growth and declining residual thyroid function. (thyroid.org)

Pregnancy and the postpartum period

Pregnancy increases thyroid hormone requirements while changing the interpretation of laboratory measurements. Estrogen raises concentrations of thyroxine-binding globulin, increasing protein-bound and total thyroxine (T4) without necessarily indicating thyroid overactivity. Human chorionic gonadotropin weakly stimulates the thyroid, which can lower thyroid-stimulating hormone (TSH), particularly in the first trimester. In women with established deficiency, levothyroxine requirements frequently rise by approximately 25–50%. These physiological changes make nonpregnant reference intervals unsuitable for interpreting some results: TSH and free T4 are assessed against pregnancy-specific intervals, with attention to gestational age and the laboratory method. (thyroid.org)

Maternal T4 crosses the placenta and supports development of the fetal brain and central nervous system. The fetus depends on maternal thyroid hormone during the first trimester; its thyroid begins functioning at about 12 weeks but does not produce sufficient hormone until approximately 18–20 weeks. Untreated overt maternal deficiency, particularly when severe, is associated with miscarriage, pre-eclampsia, anemia, low birthweight, stillbirth, and, rarely, maternal heart failure. Severe deficiency during early gestation can impair fetal neurological development. These established consequences of overt disease should not be assumed to apply with equal magnitude to every mild TSH elevation accompanied by normal free T4. (niddk.nih.gov)

Biochemical assessment distinguishes elevated TSH with low free T4 from elevated TSH with free T4 within the appropriate reference interval. The American Thyroid Association’s 2026 guidelines prioritize laboratory- and trimester-specific reference intervals rather than a single universal cutoff; they note that fixed substitutes can misclassify thyroid status. For women receiving levothyroxine, the guidelines describe TSH testing at pregnancy confirmation, approximately every four weeks during the first half of pregnancy, at least once in the third trimester, and four to six weeks after a dose adjustment. Oral levothyroxine supplies the deficient T4, with clinician-selected adjustments guided by biochemical results. After delivery, replacement requirements commonly fall toward their prepregnancy level, and postpartum testing allows further adjustment rather than continuation of an increased pregnancy dose without reassessment. (journals.sagepub.com)

Postpartum thyroiditis is an autoimmune inflammatory disorder arising during the first year after delivery. The American Thyroid Association estimates that it affects approximately 5–10% of women in the United States. Susceptibility is higher in women with thyroid autoantibodies, previous thyroid dysfunction, or type 1 diabetes. Destruction of thyroid follicles releases stored hormone, producing a transient thyrotoxic phase rather than increased hormone synthesis; subsequent depletion and impaired production can produce a hypothyroid phase. The thyrotoxic phase typically begins one to four months after delivery and lasts one to three months, whereas hypothyroidism commonly appears four to eight months after delivery. Some women experience only one phase. Palpitations and insomnia may characterize the first phase; fatigue, constipation, dry skin, and depressive symptoms may characterize the second and overlap with other postpartum conditions. (thyroid.org)

Recovery and persistent thyroid failure require distinction through follow-up testing. Most affected women regain normal thyroid function within 12–18 months after symptom onset; the American Thyroid Association estimates that approximately 20% of those entering the hypothyroid phase remain hypothyroid. Antithyroid drugs do not address the destructive thyrotoxic phase because hormone synthesis is not increased. Levothyroxine may be used during the deficient phase, and a clinician-supervised reduction after approximately six to twelve months of treatment can help establish whether replacement remains necessary. Persistent deficiency requires ongoing replacement, whereas recovery permits its discontinuation; thyroid hormone replacement is compatible with breastfeeding. (thyroid.org)

Hypothyroidism in older adults

Older adults may have fewer recognizable manifestations of thyroid hormone deficiency than younger patients. Fatigue, weakness, slowed thinking, reduced activity, and constipation overlap with age-related changes, frailty, depression, and the effects of multiple chronic diseases. In a comparative study summarized in Endotext, fatigue and weakness occurred in more than half of older hypothyroid patients, whereas cold intolerance, weight gain, paresthesias, and muscle cramps were reported less frequently than in younger patients. Cognitive or functional deterioration can therefore accompany hypothyroidism without a conspicuous cluster of classical symptoms. Conversely, these complaints alone cannot distinguish thyroid deficiency from neurological disease, medication effects, or other causes of declining function. (ncbi.nlm.nih.gov)

The population distribution of thyroid-stimulating hormone (TSH) shifts toward higher concentrations with advancing age, including among people without recognized thyroid disease or thyroid autoantibodies. In a 2007 analysis of the US National Health and Nutrition Examination Survey III, Martin I. Surks and Joseph G. Hollowell found that the 97.5th percentile of TSH was 3.56 mIU/L at ages 20–29 and 7.49 mIU/L at age 80 or older. Approximately 70% of older participants whose TSH exceeded 4.5 mIU/L nevertheless fell within their age-specific reference range. Applying a single adult upper limit can consequently overestimate subclinical hypothyroidism in older populations. These population estimates are not universal diagnostic cutoffs: interpretation also depends on the laboratory reference interval, free T4, persistence of the abnormality, and evidence of underlying thyroid disease. (pubmed.ncbi.nlm.nih.gov)

Age-specific treatment evidence also distinguishes mild biochemical abnormalities from overt hormone deficiency. The 2017 TRUST randomized controlled trial, reported by David J. Stott and colleagues, enrolled 737 adults aged at least 65 years with persistent TSH concentrations of 4.60–19.99 mIU/L and free T4 within the reference range. Mean age was 74.4 years and mean baseline TSH was 6.40 mIU/L. Although levothyroxine lowered TSH, it produced no significant improvement in hypothyroid-symptom or tiredness scores at one year compared with placebo. Participants generally had mild TSH elevations and relatively low symptom burdens; the findings do not establish that replacement is ineffective for overt hypothyroidism or for every older patient with more substantial biochemical abnormalities. (nejm.org)

Coronary artery disease influences the pace of clinician-supervised replacement because thyroid hormone increases heart rate and contractility and can provoke angina in susceptible patients. The American Thyroid Association’s 2014 guideline therefore describes cautious initiation and gradual adjustment in patients with established coronary disease. Older adults often require less levothyroxine because lean body mass and T4 turnover decline, although impaired absorption and concurrent medicines can offset this tendency. Polypharmacy introduces additional variability: calcium supplements and iron preparations can reduce levothyroxine absorption, while other drugs affect hormone metabolism. Cognitive impairment or dependence on caregivers may also complicate consistent administration. (doi.org)

Excess replacement is particularly consequential in older adults because of susceptibility to atrial fibrillation and osteoporotic fractures. The 2014 guideline cited a ten-year observational study in which adults older than 65 with TSH below 0.1 mIU/L—most receiving levothyroxine—had approximately three times the atrial-fibrillation risk of euthyroid controls. It also considered a higher treatment TSH target of 4–6 mIU/L reasonable for people older than approximately 70–80 years, while noting that direct randomized comparisons of different targets were unavailable at publication. This proposed treatment target is distinct from an age-specific diagnostic reference interval. (doi.org)

Thyroid hormone replacement

Levothyroxine (L-T4) is synthetic thyroxine, chemically equivalent to the T4 secreted by the human thyroid. Replacement supplies the missing hormone rather than stimulating a damaged gland to recover. Peripheral deiodinase enzymes convert T4 into biologically active triiodothyronine (T3); this conversion continues even when the thyroid has been surgically removed. T4 therefore supplies both circulating thyroxine and a substrate for tissue T3 production. Its approximately seven-day circulating half-life permits once-daily administration with relatively stable hormone concentrations. The American Thyroid Association’s (ATA) 2014 guideline, prepared by a task force led by Jacqueline Jonklaas, identifies levothyroxine as standard replacement therapy because of its efficacy, favorable safety profile, long clinical experience, and ease of administration. (thyroid.org)

Clinician-selected requirements depend on residual thyroid function, body size and composition, age, cardiac disease, and the clinical setting. People without functioning thyroid tissue generally require more replacement than those with autoimmune thyroid disease who retain some endogenous secretion. Lean or ideal body weight may predict requirements better than actual weight, particularly when excess adipose tissue contributes substantially to body mass. Older age commonly reduces requirements. In coronary artery disease, thyroid hormone’s effects on heart rate and contractility make the pace of replacement important because treatment can provoke angina. Pregnancy commonly increases requirements, whereas thyroid-cancer treatment may use higher doses for TSH suppression—a different objective from ordinary replacement. (pmc.ncbi.nlm.nih.gov)

Oral levothyroxine is available as tablets, soft-gel capsules, and liquid formulations. Branded and generic products contain the same active hormone, but their inactive ingredients differ. These formulations provide T4 rather than a fixed mixture of T4 and T3, leaving peripheral conversion to determine much of the active-hormone supply. The ATA distinguishes replacement, which seeks to reproduce normal thyroid function, from suppressive treatment intended to inhibit the growth of selected thyroid cancers. NICE guideline NG145, published in 2019, likewise designates levothyroxine as first-line treatment for adults, children, and young people with primary hypothyroidism. (thyroid.org)

Liothyronine is synthetic T3. Unlike levothyroxine, it supplies the active hormone directly and has a shorter duration of action; conventional oral preparations produce post-dose peaks followed by declining concentrations rather than the relatively steady exposure associated with T4. NICE does not recommend its routine use either alone or with levothyroxine, citing insufficient evidence of additional benefit and uncertainty about long-term adverse effects. The guideline’s evidence review found no important overall health benefit from combination treatment across seven randomized controlled trials. NICE’s October 2025 surveillance review found insufficient new evidence to change that recommendation. (thyroid.org)

Desiccated thyroid extract is prepared from dried animal thyroid, principally porcine tissue, and contains both T4 and T3. Its T4:T3 ratio is approximately 4.2:1, compared with about 14:1 in human thyroid secretion; its relatively high T3 content can therefore produce supraphysiological T3 concentrations and daily fluctuations. NICE recommends against natural thyroid extract for primary hypothyroidism because superiority over levothyroxine has not been established and long-term adverse effects remain uncertain. In its September 18, 2025 statement, the ATA reaffirmed synthetic levothyroxine as standard therapy and stated that desiccated extract is not recommended as first-line treatment, while acknowledging its use by some patients. (pmc.ncbi.nlm.nih.gov)

Monitoring, absorption, and long-term outcomes

Levothyroxine has a circulating half-life of approximately seven days, so hormone concentrations and pituitary feedback do not equilibrate immediately after a dose change. The American Thyroid Association’s 2014 guideline describes reassessment after 4–6 weeks, with annual testing once treatment is stable. In primary thyroid failure, thyroid-stimulating hormone (TSH) is the principal biochemical marker of replacement adequacy, interpreted against the appropriate reference interval and clinical context. Symptoms alone are insufficient to establish whether the dose is adequate. (pmc.ncbi.nlm.nih.gov) In central disease, impaired pituitary signaling makes TSH unreliable: a low TSH during treatment does not necessarily indicate excess replacement. The European Thyroid Association’s 2018 guideline instead emphasizes free T4, generally targeting concentrations above the midpoint of the reference interval. Blood sampling before the daily dose, or at least four hours afterward, limits distortion from the post-dose rise in free T4. (pmc.ncbi.nlm.nih.gov)

Oral exposure depends on both the prescribed dose and its absorption. Food can reduce or delay absorption, while iron salts, calcium supplements, certain antacids, and bile-acid sequestrants can bind or sequester levothyroxine within the gastrointestinal tract. Consistency in administration relative to meals and interacting medicines therefore affects the interpretation of serial blood tests. (thyroid.org) In a 2011 single-dose pharmacokinetic study, Isabelle Zamfirescu and Harold Carlson examined eight healthy adults: simultaneous administration of calcium carbonate, citrate, or acetate, each supplying 500 mg elemental calcium, reduced levothyroxine absorption by approximately 20–25%. This small experimental study quantified an interaction rather than establishing an identical effect in every treated patient. (pubmed.ncbi.nlm.nih.gov)

Gastrointestinal disease can also change replacement requirements. Celiac disease reduces intestinal absorption; Helicobacter pylori gastritis and autoimmune atrophic gastritis can alter gastric acidity and impair tablet dissolution. Treatment of the underlying disorder may subsequently lower the required levothyroxine dose. Drug interactions are not confined to absorption: estrogen increases thyroxine-binding globulin, whereas medicines such as phenytoin, carbamazepine, and rifampin can increase thyroid-hormone clearance. (pmc.ncbi.nlm.nih.gov) Changes in medicines, formulation, or manufacturer are therefore relevant when previously stable laboratory results change, as are missed doses and inconsistent administration. (thyroid.org)

In primary disease, persistent elevation of TSH suggests underreplacement, with low free T4 indicating overt biochemical deficiency; suppressed TSH suggests overreplacement. Excess exposure is associated with atrial fibrillation, bone loss, and fractures, particularly in older adults and postmenopausal women. (journals.sagepub.com) A 1994 study by Clark Sawin and colleagues followed adults aged at least 60 years for ten years. Atrial fibrillation developed in 28% of those with baseline TSH at or below 0.1 mIU/L, compared with 11% of those with normal TSH; the adjusted relative risk was 3.1. The cohort included people with different causes of low TSH, so these figures describe an association with biochemical thyroid excess rather than the risk attributable exclusively to levothyroxine treatment. (pubmed.ncbi.nlm.nih.gov)

Replacement resolves the signs and symptoms of hormone deficiency in most patients, but biochemical normalization and subjective recovery are not interchangeable outcomes. Permanent loss of thyroid function usually requires lifelong replacement; restoration of normal blood results during treatment does not demonstrate recovery of the gland. (pmc.ncbi.nlm.nih.gov) Conversely, destructive thyroiditis may cause temporary deficiency, allowing clinician-supervised reassessment of whether replacement remains necessary. (thyroid.org) Persistent fatigue, cognitive complaints, or reduced quality of life despite adequate biochemical replacement require consideration of other explanations, including anemia and depression, rather than automatic attribution to continuing thyroid-hormone deficiency. The 2014 guideline specifically distinguishes acknowledging persistent symptoms from assuming that further hormone escalation will resolve them. (pmc.ncbi.nlm.nih.gov)

Myxedema coma and severe decompensation

Myxedema coma is a rare, life-threatening state in which severe thyroid hormone deficiency overwhelms the mechanisms maintaining homeostasis, producing altered consciousness and multiorgan dysfunction. The name is misleading: most affected patients are not initially comatose, and conspicuous myxedema, or nonpitting tissue swelling, is not required for recognition. The syndrome therefore denotes decompensated hypothyroidism rather than a particular depth of unconsciousness. Its severity is illustrated by a Japanese national inpatient study covering July 2010–March 2013: among 149 identified cases, the mean age was 77 years, approximately two-thirds were women, and in-hospital mortality was 29.5%. The estimated annual incidence in Japan was 1.08 cases per million people; this country-specific estimate is not a universal incidence rate. (pubmed.ncbi.nlm.nih.gov)

Decompensation commonly follows an additional physiological stress, including infection, cold exposure, stroke, heart failure, gastrointestinal bleeding, or exposure to sedatives and analgesics. Patients may have experienced worsening lethargy and somnolence for weeks or months before developing confusion, stupor, or coma. Defective thermoregulation produces hypothermia, while hypoventilation, bradycardia, and hypotension indicate respiratory and cardiovascular compromise. Infection may occur without fever or the expected tachycardia. Respiratory failure reflects diminished ventilatory responses to low oxygen and elevated carbon dioxide, together with respiratory-muscle weakness; tongue swelling and pleural effusions can further impair breathing. Carbon dioxide retention, hypoxemia, hyponatremia, and hypoglycemia may aggravate impaired consciousness. (ncbi.nlm.nih.gov)

Recognition depends on the clinical pattern together with biochemical evidence of thyroid hormone deficiency, not on a single laboratory threshold. Free thyroxine is generally low, and thyroid-stimulating hormone (TSH) is usually elevated in primary thyroid failure. However, TSH may be low or normal in central hypothyroidism or suppressed by concurrent critical illness; its magnitude does not reliably measure the severity of decompensation. Hospital evaluation also assesses glucose, electrolytes, blood gases, cardiac function, and possible infection. Altered consciousness or circulatory instability cannot automatically be attributed entirely to thyroid deficiency, because sepsis and other precipitating illnesses may independently produce these abnormalities. The 2014 American Thyroid Association guideline states that treatment based on strong clinical suspicion should not be delayed while awaiting laboratory confirmation. (pmc.ncbi.nlm.nih.gov)

Management combines intensive supportive care with hormone replacement and treatment of the precipitating disorder. Ventilatory assistance may be necessary, while circulatory support requires careful assessment of volume status. Hospital teams correct glucose and electrolyte disturbances and use passive warming; aggressive peripheral warming can provoke vasodilation and worsen hypotension. Suspected infection is investigated and treated even when its usual signs are muted. Both the 2014 American Thyroid Association guideline and a 2026 joint European and British endocrine consensus statement favor initial intravenous levothyroxine. Liothyronine may be considered when conversion of T4 to T3 is impaired, but excessive exposure carries cardiac risks. These recommendations rest largely on observational reports and expert consensus rather than randomized trials. (pmc.ncbi.nlm.nih.gov)

Empirical intravenous glucocorticoid coverage precedes thyroid hormone administration because coexisting adrenal insufficiency may be unrecognized, and restoration of thyroid hormone action can increase cortisol requirements and clearance. A pretreatment cortisol sample is obtained when feasible without delaying care; glucocorticoid continuation is reassessed after adrenal evaluation. Response is judged principally by improving consciousness, cardiac function, and ventilation, supported by serial thyroid hormone measurements. TSH often improves more slowly than these clinical endpoints and is therefore unsuitable as the sole early measure of recovery. (pmc.ncbi.nlm.nih.gov)

Screening and public-health prevention

Symptom-driven diagnosis, targeted case finding, and population screening differ in the reason for testing. Diagnostic testing investigates suspected disease—for example, persistent cold intolerance and fatigue accompanied by compatible examination findings. Targeted case finding concentrates testing on people with increased susceptibility, such as those with type 1 diabetes, Down syndrome, a family history of thyroid disease, or previous irradiation of the head and neck. Population screening tests people without recognized signs or symptoms, usually according to an age-based or other eligibility rule. An increased probability of detecting biochemical abnormalities in a high-risk group does not, by itself, establish that screening improves health outcomes. (uspreventiveservicestaskforce.org)

On March 24, 2015, the United States Preventive Services Task Force (USPSTF) issued an I statement for screening nonpregnant, asymptomatic adults for thyroid dysfunction, encompassing both hypothyroidism and hyperthyroidism. This designation means that evidence is insufficient to determine the balance of benefits and harms; it is not a finding that screening is ineffective. Its scope does not encompass diagnostic evaluation of symptomatic patients, pregnancy-specific testing, or newborn screening. The USPSTF’s May 2024 literature surveillance, published on August 21, 2024, found no new studies directly evaluating thyroid screening and insufficient new evidence to warrant an updated systematic review. (uspreventiveservicestaskforce.org)

The evidence gap concerns the entire screening pathway, rather than merely whether a blood test can detect an abnormal hormone concentration. The 2015 review found no studies directly demonstrating that screening reduced morbidity or mortality. Treatment trials predominantly concerned subclinical disease: four trials involving 327 participants found no improvement in quality of life over one year. Potential harms include false-positive findings, anxiety associated with disease labeling, and treatment of abnormalities that would normalize or never cause clinical problems. Serum thyroid-stimulating hormone (TSH) is the principal adult screening test; the USPSTF described repeat measurements over three to six months to establish persistence, followed by thyroxine testing to classify persistent abnormalities. Thus, a single mildly elevated TSH result is not equivalent to established, clinically consequential deficiency. (uspreventiveservicestaskforce.org)

Iodine adequacy is a different public-health intervention: it addresses an essential substrate for thyroid hormone synthesis rather than searching for existing disease. The World Health Organization’s 2014 guideline recommended iodization of food-grade salt used in households and food processing to prevent and control iodine-deficiency disorders. This population-level fortification strategy targets deficiency-related thyroid dysfunction and developmental harm, not every cause of hypothyroidism. Adequate iodine cannot prevent an absent or malformed thyroid gland or replace tissue destroyed by autoimmune disease or surgery. Nor is greater iodine exposure invariably protective: excessive intake can cause or worsen hypothyroidism, particularly in susceptible people with autoimmune thyroid disorders. (who.int)

Newborn screening instead aims to identify congenital hormone deficiency before irreversible developmental consequences occur. In United States programs, heel-prick blood-spot collection generally occurs 24–48 hours after birth; laboratories measure TSH, thyroxine, or both. Most affected infants lack obvious symptoms at birth, making symptom-driven detection inadequate. An out-of-range result prompts diagnostic follow-up rather than constituting a diagnosis itself; collection timing, prematurity, and low birth weight can affect results. Screening does not prevent congenital thyroid maldevelopment or hormone-synthesis defects. Its preventive effect depends on timely recognition, confirmation, and hormone replacement, which can avert intellectual disability and growth failure associated with untreated deficiency. (newbornscreening.hrsa.gov)

Historical recognition and therapeutic development

In 1874, William Withey Gull published a description of an acquired disorder in adult women characterized by physical and mental slowing and changes in the skin and facial appearance. He compared it with the developmental syndrome then called “cretinism,” but did not establish thyroid failure as its cause. In 1878, William Miller Ord introduced the term myxoedema—also spelled myxedema—for the distinctive, jelly-like swelling of connective tissue. His postmortem observations included a markedly shrunken thyroid whose normal structure had largely disappeared. The name emphasized tissue changes rather than a demonstrated hormonal deficiency; these clinical descriptions preceded identification of the gland’s active secretion. (pmc.ncbi.nlm.nih.gov)

Observations after thyroid surgery supplied stronger evidence of causation. In April 1883, Theodor Kocher reported follow-up investigations drawn from 101 patients on whom he had operated in Bern. Patients whose thyroids had been completely removed developed a systemic disorder resembling severe spontaneous thyroid deficiency, whereas the course after partial removal differed. Kocher initially entertained an explanation involving chronic respiratory impairment rather than loss of an internal secretion. Victor Horsley’s subsequent thyroid-removal experiments in animals supported the latter mechanism. These observations connected congenital thyroid absence, acquired myxedema, and illness following total thyroidectomy as consequences of lost thyroid function. (pmc.ncbi.nlm.nih.gov)

George Redmayne Murray’s report, published in the British Medical Journal on October 10, 1891, described treatment with subcutaneous injections of an extract prepared from sheep thyroid glands. It provided a practical demonstration that material from a functioning gland could reverse the clinical effects of deficiency without replacing the organ surgically. (bmj.com) In 1892, Hector Mackenzie reported effective treatment by feeding fresh sheep thyroid, while Edward Fox described oral administration of thyroid extract. Oral treatment simplified replacement by avoiding repeated injections and became the basis of widespread use of animal-derived preparations. The therapeutic development thus preceded knowledge of the active substance’s chemical identity. (journals.sagepub.com)

Edward Calvin Kendall isolated crystalline thyroxine in 1914, making it possible to investigate a defined active substance rather than whole-gland material. (nature.com) Charles Robert Harington and George Barger established thyroxine’s constitution and reported its synthesis in 1927. (pmc.ncbi.nlm.nih.gov) A sodium salt introduced in 1949 improved the pharmaceutical practicality of synthetic thyroxine, or levothyroxine. Another milestone was the identification of triiodothyronine by Jack Gross and Rosalind Pitt-Rivers in 1952, alongside independent French investigations. In 1970, demonstration that people without thyroid glands could convert administered T4 into T3 supplied a physiological basis for replacing thyroid secretion with T4 alone rather than necessarily supplying both hormones. (link.springer.com)

Laboratory methods also shifted recognition away from advanced clinical disease. In 1971, Reginald Hall, Jacqueline Amos, and Brian Ormston reported a thyroid-stimulating hormone radioimmunoassay whose principal clinical application was detecting minor degrees of primary thyroid deficiency. (pmc.ncbi.nlm.nih.gov) Population-based detection followed in infancy. In May 1975, Jean Dussault and colleagues reported an automated thyroxine assay using dried blood collected on filter paper on the fifth day of life within Quebec’s newborn-screening network. Among approximately 47,000 measurements, they identified seven hypothyroid infants and three infants with low thyroxine-binding globulin. This approach made neonatal identification depend on biochemical evidence rather than waiting for conspicuous developmental or physical abnormalities. (pubmed.ncbi.nlm.nih.gov)

References

1. Chapter 2 Thyroid Hormone Synthesis And Secretionncbi.nlm.nih.gov
2. Ontogeny, Anatomy, Metabolism and Physiology of the Thyroidncbi.nlm.nih.gov
3. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Statusthyroid.org
4. Metabolism of Thyroid Hormonencbi.nlm.nih.gov
5. Thyroid Hormone Crosstalk with Nuclear Receptor Signaling in Metabolic Regulationpmc.ncbi.nlm.nih.gov
6. Thyroid Hormone Regulation of Metabolismpmc.ncbi.nlm.nih.gov
7. Hypothyroidism Web Brochurethyroid.org
8. Thyroid Hormone Treatmentthyroid.org
9. Thyroid Function Tests | American Thyroid Associationthyroid.org
10. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidismpmc.ncbi.nlm.nih.gov
11. Vol 5 Issue 5 p.5-6 | American Thyroid Associationthyroid.org
12. Congenital Hypothyroidism | American Thyroid Associationthyroid.org
13. Hypothyroidism | American Thyroid Associationthyroid.org
14. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).pubmed.ncbi.nlm.nih.gov
15. Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)scispace.com
16. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002)pubmed.ncbi.nlm.nih.gov
17. Hypothyroidism (Underactive Thyroid) - NIDDKniddk.nih.gov
18. Recommendation: Thyroid Dysfunction: Screeninguspreventiveservicestaskforce.org
19. Hashimoto's Disease - NIDDKniddk.nih.gov
20. Hashimoto’s Thyroiditis | American Thyroid Associationthyroid.org
21. Selectivity in tyrosyl iodination sites in human thyroglobulinpubmed.ncbi.nlm.nih.gov
22. Thyroiditis | American Thyroid Associationthyroid.org
23. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditispubmed.ncbi.nlm.nih.gov
24. Clinical Practice Guidelines for Hypothyroidism in Adultsthyroid.org
25. Inhibitory effect of lithium on the release of thyroid hormones from thyrotropin-stimulated mouse thyroids in a perifusion systempubmed.ncbi.nlm.nih.gov
26. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunctionpmc.ncbi.nlm.nih.gov
27. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidismendo-ern.eu
28. Hormone Replacement in Hypopituitarism Guideline Resourcesendocrine.org
29. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargementpmc.ncbi.nlm.nih.gov
30. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guidelinepmc.ncbi.nlm.nih.gov
31. Adult Hypothyroidismendotext.org
32. Adult Hypothyroidism - Endotext - NCBI Bookshelfncbi.nlm.nih.gov
33. Myxedema and Coma (Severe Hypothyroidism) - Endotext - NCBI Bookshelfncbi.nlm.nih.gov
34. The Effect of Endocrine Disorders on Lipids and Lipoproteins - Endotextncbi.nlm.nih.gov
35. Subclinical hypothyroidism and the risk of coronary heart disease and mortalitypubmed.ncbi.nlm.nih.gov
36. Pericardial diseases in patients with hypothyroidismpubmed.ncbi.nlm.nih.gov
37. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidismpubmed.ncbi.nlm.nih.gov
38. Is there a causal relationship between hypothyroidism and hyponatremia?pmc.ncbi.nlm.nih.gov
39. Effects of an acute water load on plasma ANP and AVP, and renal water handling in hypothyroidism: comparison of before and after L-thyroxine treatmentpubmed.ncbi.nlm.nih.gov
40. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic studypubmed.ncbi.nlm.nih.gov
41. Disturbances of menstruation in hypothyroidismpubmed.ncbi.nlm.nih.gov
42. Hypothyroidism (Underactive Thyroid) - NIDDKniddk.nih.gov
43. Recommendations | Thyroid disease: assessment and management | Guidance | NICEnice.org.uk
44. Hypothyroidism Web Brochurethyroid.org
45. Clinical Strategies in the Testing of Thyroid Function - Endotext - NCBI Bookshelfncbi.nlm.nih.gov
46. Biotin supplement use is common and can lead to the false measurement of thyroid hormone in commonly used assaysthyroid.org
47. Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulinpmc.ncbi.nlm.nih.gov
48. Final Recommendation Statement: Thyroid Dysfunction: Screening | United States Preventive Services Taskforceuspreventiveservicestaskforce.org
49. Thyroid Health Blog: An Approach to the Patient with Thyroid Disease and High Symptom Burden | American Thyroid Associationthyroid.org
50. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health studypubmed.ncbi.nlm.nih.gov
51. 2013 ETA Guideline: Management of Subclinical Hypothyroidismpmc.ncbi.nlm.nih.gov
52. Levothyroxine for subclinical hypothyroidism in people under 65nice.org.uk
53. Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update—An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinologypmc.ncbi.nlm.nih.gov
54. Hypothyroidism in Children and Adolescents | American Thyroid Associationthyroid.org
55. Hypothyroidism in Pregnancy | American Thyroid Associationthyroid.org
56. Thyroid Disease & Pregnancy - NIDDKniddk.nih.gov
57. Clinical Thyroidology for the Public – Highlighted Article | American Thyroid Associationthyroid.org
58. Thyroid Health – Management of Hypothyroidism During Pregnancy: When and how to treat? | American Thyroid Associationthyroid.org
59. Postpartum Thyroiditis | American Thyroid Associationthyroid.org
60. Hypothyroidism in Older Adults - Endotext - NCBI Bookshelfncbi.nlm.nih.gov
61. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism.pubmed.ncbi.nlm.nih.gov
62. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacementpmc.ncbi.nlm.nih.gov
63. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacementpubmed.ncbi.nlm.nih.gov
64. Rationale and impact: Thyroid disease—assessment and managementnice.org.uk
65. October 2025 exceptional surveillance of thyroid disease: assessment and management (NICE guideline NG145)nice.org.uk
66. American Thyroid Association Statement on Desiccated Thyroid Extractthyroid.org
67. Absorption of levothyroxine when coadministered with various calcium formulationspubmed.ncbi.nlm.nih.gov
68. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older personspubmed.ncbi.nlm.nih.gov
69. Myxedema and Coma (Severe Hypothyroidism)pubmed.ncbi.nlm.nih.gov
70. Myxedema coma of both primary and secondary origin, with non-classic presentation and extremely elevated creatine kinase.pubmed.ncbi.nlm.nih.gov
71. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japanpubmed.ncbi.nlm.nih.gov
72. Myxedema Coma - StatPearlsncbi.nlm.nih.gov
73. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacementpmc.ncbi.nlm.nih.gov
74. Management of endocrine emergencies: joint consensus statement for management of myxoedema comapmc.ncbi.nlm.nih.gov
75. Hypothyroidism in Older Adultsendotext.org
76. Recommendation: Thyroid Dysfunction: Screeninguspreventiveservicestaskforce.org
77. Screening for Thyroid Dysfunction: Literature Surveillance Reportuspreventiveservicestaskforce.org
78. Hypothyroidism (Underactive Thyroid) - NIDDKniddk.nih.gov
79. Guideline: fortification of food-grade salt with iodine for the prevention and control of iodine deficiency disorderswho.int
80. Newborn Screening Processnewbornscreening.hrsa.gov
81. Congenital Hypothyroidismnewbornscreening.hrsa.gov
82. Hypothyroidism and Thyroid Substitution: Historical Aspectspmc.ncbi.nlm.nih.gov
83. The Chemical Constitution of Thyroxinenature.com
84. Chemistry of Thyroxine: Constitution and Synthesis of Thyroxinepmc.ncbi.nlm.nih.gov
85. Thyroxine and treatment of hypothyroidism: seven decades of experiencelink.springer.com
86. Radioimmunoassay of Human Serum Thyrotrophinpmc.ncbi.nlm.nih.gov
87. Preliminary report on a mass screening program for neonatal hypothyroidismpubmed.ncbi.nlm.nih.gov